Brian Nicol gets to work at Starbucks.

Motleyful money starts now.

I'm Dylan Lewis, and I'm joined over the airwaves by Motleyful analyst Anthony Chavone.

Anthony, thanks for joining me today.

Thanks for having me, Dylan.

We've got a fresh couple

of results at Starbucks and also a little bit of corporate intrigue with some poison pills

and potential acquisition targets. We're going to kick off today talking Starbucks, though,

and fresh results out from them, and there seems to be so much excitement about the Brian

Nicolera, but when we look at the

actual numbers for the business, Anthony, it feels like the story is pretty similar to where it was

a couple quarters ago. Yeah, Dylan, no surprise here. It was a brutal quarter for Starbucks. Revenue

of 9.4 billion was flat from the prior year. Global comparable store sales declined

4%. And that was largely driven by weak sales in the U.S. operating margins. They contracted by

about 380 basis points. And then on the bottom line, earnings per share fell about 22% for the previous

year. So, you know, as we're recording us, I think Starbucks is up about 6% today.

So even though the results were not good, it was better than the market expected.

So that's why the shares are higher today.

So I guess, you know, less bad news is good news for Starbucks in this case.

When I've been trying to keep tabs on what's going on with Starbucks,

I feel like a lot of the story has been customer expectations and habits

and the pricing story a little bit with them.

...